Aptar Pharma extends its CR nasal pump manufacturing capabilities in North America

Aptar Pharma’s Child-Resistant Feature for nasal sprays combines Child-Resistance (CR) and Senior-Friendliness (SF) with its intuitive and widely-accepted squeeze-and-turn technology.

Aptar Pharma announced the installation of manufacturing capacity for its Child-Resistant and Senior-Friendly Classic Nasal Pump in their Congers, NY site.

Effective April 2017, a new assembly machine for Aptar Pharma’s Child-Resistant (CR) feature for nasal sprays was transferred from Aptar Pharma’s plant in Southern Germany to Congers, NY. This brings its manufacturing capacity closer to the target market for which this pump has been successfully established. Aptar Pharma Congers site, NY.

The company release informed, Aptar Pharma’s Child-Resistant technology platform was developed primarily for the U.S. market when, in 2012, the US Consumer Product Safety Commission (CPSC) issued a rule requiring Child-Resistant packaging for any over-the-counter or drug product containing the equivalent of 0.08 milligrams or more of imidazoline (16 CFR Part 1700.14), a formulation widely used in nasal decongestant topical sprays.

Less than two years after the rule’s announcement, Aptar Pharma introduced its newly-engineered Child-Resistant/ Senior-Friendly nasal spray pump to the U.S. market, which successfully matched the CPSC requirements.

Reportedly, Aptar Pharma’s Child-Resistant Feature for nasal sprays combines Child-Resistance (CR) and Senior-Friendliness (SF) with its intuitive and widely-accepted squeeze-and-turn technology.